The firm's full-year 2024 revenues increased 79 percent year over year to $4.3 million.

The diagnostic test and sample management solutions developer intends to use cash on hand to fund the repurchase.

Last week, readers were most interested in a story about layoffs at Cepheid that will take effect in May.

The company also reported that its fourth quarter revenues dropped 7 percent from a year ago, while its full-year 2024 revenues declined 3 percent.

The New England-based firms said that they are developing a rapid at-home test that will be used to detect cancer biomarkers in interstitial fluid samples.

News items for the week of March 17, 2025.

Grifols will enhance its analytical technologies with Inpeco's open automation system FlexLab X.

The investment bank views the company as a promising target with a strong track record and prospects for expansion into new, under-penetrated markets.

The employees are located in California's Alameda County, San Joaquin County, and Santa Clara County.

The firms said that they will integrate Primaa's skin cancer testing algorithms with Gestalt's PathFlow digital pathology software platform.